SCHEMBL573170

SCHEMBL573170

CC(C)(C)[Si](C)(C)OCCC=O

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DUT P33316 2/20 0.35
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29102792 0.88 DUT (0.41) DUT
SCHEMBL852468 0.87 DUT (0.40) DUT
SCHEMBL201004 0.85 DUT (0.39) DUT
SCHEMBL2917304 0.84 TSHR (0.40) DUT
SCHEMBL27241090 0.84 TSHR (0.40) DUT
SCHEMBL31240526 0.84 TSHR (0.40) DUT
SCHEMBL1008596 0.84 TSHR (0.40) DUT
SCHEMBL5889630 0.82 DUT (0.31) DUT
SCHEMBL18377988 0.81 DUT (0.33) DUT
SCHEMBL14244960 0.81 DUT (0.33) DUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 721 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119822916-A Chiral alpha-aryl alkyne compound and synthesis method thereof 同济大学 2025-04-15 CN claimed
WO-2026103814-A1 IRREVERSIBLE FAP INHIBITOR AND USE THEREOF 南京科络思生物科技有限公司 2026-05-21 WO disclosed
EP-4728073-A1 OLIGONUCLEOTIDE FORMULATION Ractigen Therapeutics (CN) 2026-04-22 EP disclosed
EP-4689615-A2 BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC ACTIVATION Promega Corporation (US) 2026-02-11 EP disclosed
EP-4680609-A1 KRAS MODULATORS AND USES THEREOF Quanta Therapeutics, Inc. (US) 2026-01-21 EP disclosed
US-12522615-B2 Macrocyclic compounds and derivatives as EGFR inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2026-01-13 US disclosed
WO-2025264818-A1 STAT6 MODULATORS AND METHODS OF USES THEREOF RAYTHERA, INC. (US) 2025-12-26 WO disclosed
US-20250388568-A1 NLRP3 INHIBITORS KODIAK SCIENCES INC (US) 2025-12-25 US disclosed
US-20250387397-A1 SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE MERCK SHARP & DOHME LLC (US) 2025-12-25 US disclosed
EP-3883576-B1 SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE MERCK SHARP & DOHME LLC (US) 2025-12-17 EP disclosed
EP-0532423-A1 Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine MERRELL DOW PHARMACEUTICALS INC. (US) 1993-03-17 EP disclosed
US-5142039-A β-lactam antibiotics ELI LILLY AND COMPANY (US) 1992-08-25 US disclosed
WO-1992001698-A1 ANTIVIRAL PHOSPHONO-ALKEN DERIVATIVES OF PURINES BEECHAM GROUP PLC (GB) 1992-02-06 WO disclosed
US-5004753-A Novel carboxylic acid esters, method for their production and insecticides containing them as active ingredient SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1991-04-02 US disclosed
US-4983732-A CEHMICAL INTERMEDIATES FOR BETA-LACTAM ANTIBIOTICS ELI LILLY AND COMPANY (US) 1991-01-08 US disclosed
US-4892942-A 1-CARBA (DETHIA)CEPHALOSPORINS ELI LILLY AND COMPANY (US) 1990-01-09 US disclosed
EP-0301877-A1 A method of deprotection of 3-amino azetidinones ELI LILLY AND COMPANY (US) 1989-02-01 EP disclosed
US-4791106-A 1-Carbacephalosporin antibiotics ELI LILLY AND COMPANY (US) 1988-12-13 US disclosed
EP-0291045-A2 Novel carboxylic acid esters, method for their production and insecticides containing them as an active ingredient SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-11-17 EP disclosed
EP-0232623-A1 1-Carbacephalosporin antibiotics ELI LILLY AND COMPANY (US) 1987-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388568-A1 NLRP3 INHIBITORS NLRP3, NOD1, NLRP1 DUT 4628/4885ALDH1A1 3213/4885
US-20250387397-A1 SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE ADORA2A, ADORA2B, ADORA1 DUT 933/4885ALDH1A1 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.